Welcome to our dedicated page for APOLLOMICS news (Ticker: APLMW), a resource for investors and traders seeking the latest updates and insights on APOLLOMICS stock.
Apollomics Inc (APLMW) is a clinical-stage biopharmaceutical leader developing novel oncology therapies through targeted molecular approaches and combination treatments. This dedicated news hub provides investors and industry professionals with timely updates on the company's clinical trials, regulatory milestones, and strategic initiatives.
Access verified information about Apollomics' innovative work in non-small cell lung cancer, acute myeloid leukemia, and other treatment-resistant cancers. The page aggregates official announcements including clinical trial results, partnership agreements, financial disclosures, and scientific presentations.
Key focus areas include progress updates for lead candidates vebreltinib (c-Met inhibitor) and uproleselan (E-selectin antagonist), along with developments across six clinical-stage oncology programs. Users will find essential context about the company's precision medicine strategies and therapeutic mechanisms.
Bookmark this page for structured access to Apollomics' latest advancements in cancer treatment innovation. Check regularly for authoritative updates on pipeline developments directly impacting the oncology biopharma landscape.
Apollomics Inc. (Nasdaq: APLM, APLMW) announced that Co-Founder and President, Sanjeev Redkar, will present at the 23rd Annual R. Bryan Miller Symposium on April 14, 2023, at UC Davis. Dr. Redkar's talk, titled 'The HGF/cMet Pathway in Cancer – Early Development to Clinical Evidence', will highlight the significance of the HGF/cMet pathway in cancer progression and treatment resistance. This pathway is crucial due to its association with gene mutations that drive tumor growth. Apollomics is advancing APL-101, a selective c-Met inhibitor aimed at treating non-small cell lung cancer and brain tumors. Additional notable speakers include Paula T. Hammond from MIT and David R. Liu from Harvard. Details about the symposium and speaker schedule are available on the UC Davis site.
Apollomics Inc. has completed its business combination with Maxpro Capital Acquisition Corp., allowing its Class A ordinary shares and public warrants to start trading on the Nasdaq Capital Market under the ticker symbols APLM and APLMW as of March 30, 2023. The deal, approved by Maxpro’s shareholders, raised $23.65 million through a private investment in public equity (PIPE) financing, enhancing Apollomics' capacity to develop its oncology pipeline, which includes nine drug candidates. The company aims to address treatment-resistant cancers and expects critical clinical trial results this year that could support regulatory filings.
FAQ
What is the current stock price of APOLLOMICS (APLMW)?
What is the market cap of APOLLOMICS (APLMW)?
